SURF

Surface Oncology, Inc. (SURF) | Rumor.io

Surface Oncology

SURF

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SURF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.03	0% new	0% +0	0% +0

Jun 21

Analysts from JonesTrading, Robert W. Baird, H.C. Wainwright, and Wedbush downgraded their ratings on Surface Oncology to hold on June 20 and 19, 2023.
The company is expected to show a strong revenue growth of 21.55% yearly.
A large trade of 1 million shares was executed without affecting the price, suggesting that something may be up with the company.

Generated by AI

Sentiment

Of the messages about SURF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% 0	83.19% +3.42
Bearish	100%	100%	100% 0	16.81% -3.42

Bullish· Jun 16

Surface Oncology, Inc. ($SURF) has a high relative volume (138 RVOL) and has popped 35% in trading, making it a stock to keep an eye on.
The company has a buyout deal in place for up to $65 million, which could lead to a significant spike in the stock price.
Surface Oncology's low market capitalization ($50 million) compared to the buyout price ($100 million) suggests that the company is undervalued and could see a significant increase in value.

Bearish· Jun 16

Surface Oncology, Inc. (SURF) has significantly reduced its cash reserves, from $100M to $25M in just one quarter, raising concerns about the company's financial health.
The proposed buyout of SURF by GSK is seen as a poor deal for shareholders, with the company's valuation having decreased from $1.2B in 2020 to a current price of $1.07 per share.
The company's management has been accused of selling out to GSK for "pennies" and engaging in "share printing" to benefit board members and the CEO, leading to accusations of fraud and poor leadership.

Generated by AI

Topics

Of the messages about SURF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	100%	48.97%
Analysts	—	0%	0%	0%
Announcements	—	0%	0%	43.81%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	7.22%
Macro	—	0%	0%	0%

Announcements· Jun 16

Coherus BioSciences (CHRS) will acquire Surface Oncology (SURF) in a deal worth up to $65 million, with SURF shareholders receiving CHRS stock and options.
The acquisition adds two clinical-stage assets to CHRS' portfolio, targeting the tumor microenvironment, and will advance SURF's pipeline with anti-IL-27 and anti-CCR8 programs.
SURF shares have rallied 32-55% on the news, with a market capitalization of around $48 million, while CHRS' market cap has fallen over $116 million.

Technical Analysis· May 21

Surface Oncology, Inc. ($SURF) has shown a strong move up, with some traders taking profits at resistance levels and others holding out for further gains.
The stock's price action has been characterized by a break above its VWAP (Volume-Weighted Average Price), with some traders expecting a potential squeeze if it continues to rise.
The company's stock has also been subject to bearish commentary, with some traders warning of a potential reversal and others advising against shorting the stock due to its history of fakeouts.

Generated by AI

Community

Of the messages about SURF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	1.44%
Newcomers	—	100%	100%	98.56%

Regulars· Jun 16

Coherus BioSciences has agreed to acquire Surface Oncology, Inc. for approximately $65M in stock, with the acquisition making Surface Oncology eligible for milestone agreements.
The acquisition will advance Surface Oncology's pipeline, particularly with its anti-IL-27 and anti-CCR8 programs, and multiple Phase 2 trials in solid tumors are ongoing.
The stock has seen significant price movements, including a 35% increase since the previous trading day close and a trading halt, with the company's shares presently trading at $1.00.

Newcomers· Jun 16

The merger between Coherus Biosciences and Surface Oncology, Inc. (SURF) is expected to be completed in Q3, adding two clinical-stage assets to Coherus' portfolio.
The acquisition of SURF is seen as a potential long opportunity or arb play, with some investors believing that the stock is being mispriced.
SURF's pipeline, which includes the drug Toripalimab, has the potential to pan out, with one investor joking that the company's CEO could "come out smelling like a rose" if the pipeline is successful.

Generated by AI

Also Discussed

Investors talking about SURF also mention

#	Name	Attention
1	Coherus Oncology, Inc.CHRS	0%0
2	JNCE - Jounce Therapeutics, Inc.	——
3	Arcus Biosciences, Inc.RCUS	0%new
4	ONCT - Oncternal Therapeutics, Inc.	——
5	BPMC - Blueprint Medicines Corporation	——
6	RPTX - Repare Therapeutics Inc.	——
7	PSTX - Poseida Therapeutics, Inc.	——
8	Evogene Ltd.EVGN	0%new
9	MacroGenics Inc.MGNX	0%+0
10	ALX Oncology Holdings Inc.ALXO	0%0